Immunome, Inc. and Zentalis Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug Conjugate (ADC) with best-in-class potential on track for IND submission in first quarter of 2025, and Zentalis' proprietary ADC platform technology. Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zentalis will be eligible to receive up to $275 million of milestone payments for ZPC-21 and the platform technology in addition to mid-to-high single-digit royalties.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.29 USD | -2.92% | +11.47% | +43.97% |
May. 02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
15.29 USD | -2.92% | +11.47% | 944M | ||
11.62 USD | -0.73% | +3.06% | 832M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.97% | 944M | |
+8.49% | 105B | |
-1.18% | 104B | |
+5.79% | 22.94B | |
-12.66% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.43% | 16.96B | |
+8.05% | 14.16B | |
+38.95% | 12.63B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate